Clinical Trial Detail

NCT ID NCT03396952
Title Prostaglandin Inhibition and PD-1/CTLA4 Blockade in Melanoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of California, San Francisco
Indications

melanoma

Therapies

Ipilimumab + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.